Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs C.H. Robinson Worldwide, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while C.H. Robinson Worldwide, Inc. trades at $193.5 (market cap $22.81B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and C.H. Robinson Worldwide, Inc. pays a 1.3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CHRW | |
|---|---|---|
Market Cap | $39.89B | $22.81B |
Sector | Health | Industrials |
52-Week High | $491.22 | $200.59 |
52-Week Low | $278.09 | $96.82 |
Enterprise Value | $38.15B | $24.29B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CHRW trades at $193.5, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $199.25. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.35 surpassing the $1.23 estimate. The company maintains strong profitability with a 34.84% ROE and recently acquired DeSpir Logistics to enhance high-value cargo capabilities, signaling strategic growth initiatives.
The outlook is positive, supported by earnings momentum and operational efficiency, but risks include a high P/E ratio of 39.17 suggesting premium valuation, exposure to freight market cyclicality, and competitive pressures in the logistics sector. Upside potential hinges on continued execution and industry recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
